277 related articles for article (PubMed ID: 20164655)
1. Time to move to targeted drugs in biliary tract cancer?
Louvet C; Tournigand C
Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
[No Abstract] [Full Text] [Related]
2. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
3. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
[TBL] [Abstract][Full Text] [Related]
4. Gall bladder cancer, extrahepatic bile duct cancer and ampullary carcinoma in New Zealand: Demographics, pathology and survival.
Koea J; Phillips A; Lawes C; Rodgers M; Windsor J; McCall J
ANZ J Surg; 2002 Dec; 72(12):857-61. PubMed ID: 12485219
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.
Roth A; Schleyer E; Schoppmeyer K; Kluge R; Wittekind C; Mössner J; Wiedmann M
Onkologie; 2011; 34(8-9):469-70. PubMed ID: 21934349
[No Abstract] [Full Text] [Related]
6. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
[TBL] [Abstract][Full Text] [Related]
7. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Chang PY; Cheng MF; Lee HS; Hsieh CB; Yao NS
Onkologie; 2010; 33(1-2):45-7. PubMed ID: 20164661
[TBL] [Abstract][Full Text] [Related]
10. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC).
Ji JH; Song HN; Kim RB; Oh SY; Lim HY; Park JO; Park SH; Kim MJ; Lee SI; Ryou SH; Hwang IG; Jang JS; Kim HJ; Choi JY; Kang JH
Jpn J Clin Oncol; 2015 Mar; 45(3):256-60. PubMed ID: 25628352
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and management of intrahepatic cholangiocarcinoma.
Farges O; Fuks D
Gastroenterol Clin Biol; 2010 Mar; 34(3):191-9. PubMed ID: 20202770
[No Abstract] [Full Text] [Related]
12. BINGO: targeted therapy for advanced biliary-tract cancer.
Valle JW
Lancet Oncol; 2014 Jul; 15(8):778-80. PubMed ID: 24852117
[No Abstract] [Full Text] [Related]
13. [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].
Wiedmann M; Schoppmeyer K; Witzigmann H; Hauss J; Mössner J; Caca K
Z Gastroenterol; 2005 Mar; 43(3):305-15. PubMed ID: 15765304
[TBL] [Abstract][Full Text] [Related]
14. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
17. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
[TBL] [Abstract][Full Text] [Related]
18. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
[TBL] [Abstract][Full Text] [Related]
19. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
20. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
